Can Serve Free LLC offers specialized investment advisory expertise to Clients who desire to understand oncology financial market dynamics and wisely build investment portfolios comprised of company stocks that fight Prostate Cancer.
The Global Prostate Cancer Market size was estimated at USD 12 billion in 2022, and it is expected to reach USD 27.51 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period from 2023 to 2032.
Prostate cancer has become the second most common type of cancer affecting men (skin cancer is the most prominent for men), with approximately 240,000 patients diagnosed each year, The market is witnessing growth due to factors such as the adoption of novel screening and diagnostic technologies, and government support for new therapies to cure prostate cancer. The adoption of novel screening and diagnostic technologies is projected to promote the adoption of new therapeutics. Recent breakthroughs in therapies use bioinformatics and computational biology technologies to obtain optimal treatment.
Hormonal therapy drug class segment dominated the market in 2022 with a revenue share of 88.42% in 2022. Chemotherapy drug class is expected to grow at a significant growth rate of 8.0% over the forecast period. Immunotherapy is projected to demonstrate a positive growth trend over the forecast period.
North America dominated the prostate cancer therapeutics market and accounted for the largest revenue share of 41.1% in 2022, due to an increase in the disease's prevalence, and a strong need for prostate cancer therapeutic products in the region. The Asia-Pacific region is estimated to demonstrate the fastest growth of 9.7% over the forecast period.
For additional information on Prostate Cancer, please review the video by Medical Centric.